Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Serge Gauthier

Showing results (261-270 of 370) with videos related to

Pageof 37
Sort By:
Frontiers in Psychology|August 14, 2023
Effects of virtual reality guided meditation in older adults: the protocol of a pilot randomized controlled trialKarin Cinalioglu, Paola Lavín, Magnus Bein, et al.
Alzheimer'S & Dementia (New York, N. Y.)|September 30, 2020
Agitation and impulsivity in mid and late life as possible risk markers for incident dementiaDaniel R Bateman, Sascha Gill, Sophie Hu, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|June 2, 2007
Clinical diagnostic criteria for dementia associated with Parkinson's diseaseMurat Emre, Dag Aarsland, Richard Brown, et al.
Journal of Alzheimer'S Disease : JAD|January 7, 2017
The Mild Behavioral Impairment Checklist (MBI-C): A Rating Scale for Neuropsychiatric Symptoms in Pre-Dementia PopulationsZahinoor Ismail, Luis Agüera-Ortiz, Henry Brodaty, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 2, 2020
Determining Amyloid-β Positivity Using <sup>18</sup>F-AZD4694 PET ImagingJoseph Therriault, Andrea L Benedet, Tharick A Pascoal, et al.
Journal of Alzheimer'S Disease : JAD|February 18, 2009
Methodological issues in primary prevention trials for neurodegenerative dementiaSandrine Andrieu, Nicola Coley, Paul Aisen, et al.
Alzheimer'S Research & Therapy|February 19, 2025
The impact of kidney function on Alzheimer's disease blood biomarkers: implications for predicting amyloid-β positivityBurak Arslan, Wagner S Brum, Ilaria Pola, et al.
Molecular Psychiatry|June 28, 2020
Amyloid-beta modulates the association between neurofilament light chain and brain atrophy in Alzheimer's diseaseMin Su Kang, Arturo Aliaga Aliaga, Monica Shin, et al.
Lancet (London, England)|November 20, 2016
Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trialSerge Gauthier, Howard H Feldman, Lon S Schneider, et al.
Brain Communications|May 7, 2021
Plasma levels of phosphorylated tau 181 are associated with cerebral metabolic dysfunction in cognitively impaired and amyloid-positive individualsFiroza Z Lussier, Andréa L Benedet, Joseph Therriault, et al.
Pageof 37

Showing results (261-270 of 370) with videos related to

Sort By:
Pageof 37
Frontiers in Psychology|August 14, 2023
Effects of virtual reality guided meditation in older adults: the protocol of a pilot randomized controlled trialKarin Cinalioglu, Paola Lavín, Magnus Bein, et al.
Alzheimer'S & Dementia (New York, N. Y.)|September 30, 2020
Agitation and impulsivity in mid and late life as possible risk markers for incident dementiaDaniel R Bateman, Sascha Gill, Sophie Hu, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|June 2, 2007
Clinical diagnostic criteria for dementia associated with Parkinson's diseaseMurat Emre, Dag Aarsland, Richard Brown, et al.
Journal of Alzheimer'S Disease : JAD|January 7, 2017
The Mild Behavioral Impairment Checklist (MBI-C): A Rating Scale for Neuropsychiatric Symptoms in Pre-Dementia PopulationsZahinoor Ismail, Luis Agüera-Ortiz, Henry Brodaty, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 2, 2020
Determining Amyloid-β Positivity Using <sup>18</sup>F-AZD4694 PET ImagingJoseph Therriault, Andrea L Benedet, Tharick A Pascoal, et al.
Journal of Alzheimer'S Disease : JAD|February 18, 2009
Methodological issues in primary prevention trials for neurodegenerative dementiaSandrine Andrieu, Nicola Coley, Paul Aisen, et al.
Alzheimer'S Research & Therapy|February 19, 2025
The impact of kidney function on Alzheimer's disease blood biomarkers: implications for predicting amyloid-β positivityBurak Arslan, Wagner S Brum, Ilaria Pola, et al.
Molecular Psychiatry|June 28, 2020
Amyloid-beta modulates the association between neurofilament light chain and brain atrophy in Alzheimer's diseaseMin Su Kang, Arturo Aliaga Aliaga, Monica Shin, et al.
Lancet (London, England)|November 20, 2016
Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trialSerge Gauthier, Howard H Feldman, Lon S Schneider, et al.
Brain Communications|May 7, 2021
Plasma levels of phosphorylated tau 181 are associated with cerebral metabolic dysfunction in cognitively impaired and amyloid-positive individualsFiroza Z Lussier, Andréa L Benedet, Joseph Therriault, et al.
Pageof 37